ZEALAND PHARMA/S (NASDAQ:ZEAL) Price Target Increased to $42.00 by Analysts at Needham & Company LLC

ZEALAND PHARMA/S (NASDAQ:ZEAL) had its price objective boosted by Needham & Company LLC from $32.00 to $42.00 in a research note issued to investors on Friday, The Fly reports. Needham & Company LLC currently has a buy rating on the stock.

Several other brokerages have also recently weighed in on ZEAL. Zacks Investment Research reiterated a buy rating and issued a $30.00 price objective on shares of ZEALAND PHARMA/S in a research note on Saturday, October 26th. Goldman Sachs Group upgraded shares of ZEALAND PHARMA/S from a neutral rating to a buy rating and set a $41.00 price objective for the company in a research note on Tuesday, October 15th. ValuEngine cut shares of ZEALAND PHARMA/S from a hold rating to a sell rating in a research report on Wednesday, October 2nd. TheStreet cut shares of ZEALAND PHARMA/S from a c rating to a d+ rating in a research report on Friday, August 16th. Finally, Morgan Stanley boosted their target price on shares of ZEALAND PHARMA/S from $29.00 to $30.00 and gave the company an overweight rating in a research report on Monday, August 19th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $36.25.

ZEALAND PHARMA/S stock traded down $1.97 during mid-day trading on Friday, reaching $31.33. The company’s stock had a trading volume of 8,900 shares, compared to its average volume of 7,218. ZEALAND PHARMA/S has a 12 month low of $11.55 and a 12 month high of $34.56. The business’s 50 day simple moving average is $27.43 and its 200 day simple moving average is $23.08. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of 10.44 and a beta of 2.08.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.10). The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $7.50 million. As a group, analysts predict that ZEALAND PHARMA/S will post -2.68 earnings per share for the current fiscal year.

An institutional investor recently raised its position in ZEALAND PHARMA/S stock. Farallon Capital Management LLC grew its position in ZEALAND PHARMA/S (NASDAQ:ZEAL) by 5.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,000,000 shares of the company’s stock after buying an additional 51,300 shares during the quarter. Farallon Capital Management LLC owned 3.25% of ZEALAND PHARMA/S worth $21,550,000 as of its most recent SEC filing. Institutional investors own 9.07% of the company’s stock.

ZEALAND PHARMA/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Featured Article: Market Indexes

The Fly

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.